The FDA has granted investigational new drug clearance to Nanoscope Therapeutics for a phase 2 trial investigating MCO-010 in patients with Stargardt macular degeneration, according to a press release.
“This is another important milestone for Nanoscope, giving us the opportunity of conducting a second clinical trial in the U.S. of our proprietary MCO gene therapy platform, designed to restore vision for patients suffering from retinal degenerative diseases,” Sulagna Bhattacharya, CEO of Nanoscope Therapeutics, said in the release.
MCO-010, a “multi-characteristic opsin